469 Studies Now Enrolling
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Study of IMC-F106C in Combination with Nivolumab in Patients with Advanced Melanoma
| Sponsor: | Immunocore |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU9777 |
| U.S. Govt. ID: | NCT06112314 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to see if IMC-F106C, in combination with nivolumab, works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing or shrink. IMC-F106C has not yet been approved by the Food and Drug Administration (FDA). Nivolumab and the combination of nivolumab + relatlimab is FDA approved but not in combination with IMC-F106C.
